antipsychotic

Medicare Part D’s Impact on Antipsychotic Drug Use and Costs Among Elderly Patients Without Prior Drug Insurance

Abstract: Medicare part D’s implementation improved access to and affordability of prescription drugs for the elderly without prior drug insurance. Effects for specific drugs and drug classes are less well understood. We assessed part D’s impact on antipsychotic medication (APM) utilization and out-of-pocket costs among elderly without prior drug insurance.

Variation in Antipsychotic Treatment Choice Across US Nursing Homes

Objective: Despite serious safety concerns, antipsychotic medications continue to be used widely in US nursing homes. The objective of this study was to quantify the variation in antipsychotic treatment choice across US nursing homes, and to characterize its correlates.
Methods: Prescribing practices were assessed in a cohort of 65,618 patients 65 years or older in 45 states who initiated treatment with an antipsychotic medication after nursing home admission between 2001 and 2005, using merged Medicaid; Medicare; Minimum Data Set; and Online Survey, Certification, and Reporting data.

All-Cause Mortality and Medication Risk Factors in Schizophrenia: A Prospective Cohort Study

Background: It is well established that persons with schizophrenia have high mortality rates. There is conflicting evidence that antipsychotic and perhaps other medications routinely used to treat schizophrenia contribute to mortality risk.
Methods: A health insurer database was used to examine schizophrenia diagnosis and mortality in 2008. Information from the period 2006–2008 was used to analyze demographics and medication prescriptions.

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

Neuropsychopharmacology 37,
660 (February 2012). doi:10.1038/npp.2011.238

Authors: Joo-Cheol Shim, Do-Un Jung, Sung-Soo Jung, Young-Soo Seo, Deuk-Man Cho, Ji-Heon Lee, Sae-Woom Lee, Bo-Geum Kong, Je-Wook Kang, Min-Kyung Oh, Sang-Duk Kim, Robert P McMahon
& Deanna L Kelly

Prediabetes in patients treated with antipsychotic drugs.

Manu P, Correll C, van Winkel R, et al.  | |  

Applied Monitoring for Tardive Dyskinesia and Other Extrapyramidal Side Effects

John E. Kalachnik, M.Ed.
Woodward Resource Center
Iowa Department of Human Services
Woodward, IA 

Note: The author does not represent the State of Iowa nor its policies, procedures, or positions.

The 2012 Annual Meeting will feature John Kalachnik, M.Ed., providing a 1-hour overview of drug-induced movement disorders, rating scales and applied monitoring. This will be followed by a 1 hour learning lab session allowing for hands-on experience in utilizing common rating scales used to assess movement disorders. Kalachnik is the Director of Integrated Services for the Woodward Resource Center and is one of the original authors of the Dyskinesia Identification System-Condensed User Scale (DISCUS). Register for the 2012 Annual Meeting now and plan to attend this excellent programming.

Antipsychotic use and metoclopramide

Hi list,   Anyone have a policy and/or recommendation regarding use of Reglan and antipsychotics?  Lexicomp flags the combo as an X type interaction.  We've had two instances in last month of patients being discharged on Invega ...

Wellbutrin and Antipsychotics

Would a combination of Wellbutrin and any antipsychotic be warranted in any cases?  Would this hypothetically just counteract and cancel each other out?   Christopher Ching, PharmD Inpatient Pharmacist Kaiser Permanente ...

Drug-Induced Movement Disorders

Jack J. Chen, PharmD, FCCP, BCPS, CGP
Associate Professor
Loma Linda University
Loma Linda, CA

This comprehensive review covers approaches for both the recognition and management of drug-induced movement disorders. Pharmacotherapeutic approaches for treating akathisia, dystonia, Parkinsonism and tardive dyskinesia are explored. The importance of early detection via periodic assessment is discussed.

This page may contain content contributed by CPNP members or aggregated from other online sources. This content is provided as an unmoderated service to members for civil discussion and collaboration. Any opinions, conclusions, or recommendations are those of the author. If you come across any abuse or violation of the terms of use, please report the abuse.